- Augurex to attend and sponsor Ten Topics in Rheumatology 2025, July 3–4 in London, UK.
- Showcasing biomarker-based diagnostics: JOINTstat® for rheumatoid arthritis and SPINEstat™, a first-in-class diagnostic for axial spondyloarthritis
Vancouver, Canada – June 26, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced it will sponsor and attend Ten Topics in Rheumatology 2025, taking place July 3–4 in London, UK.
As one of the premier clinical conferences for practicing rheumatologists, Ten Topics brings together national and international clinicians and industry experts to explore emerging innovations and practical, evidence-based strategies in autoimmune and inflammatory disease management.
At this year’s event, Augurex will showcase its biomarker-driven diagnostic solutions designed to address persistent challenges in both the diagnosis and management of rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA). These are two progressive autoimmune conditions where delayed identification and suboptimal monitoring can lead to poorer outcomes. Augurex’s solutions aim to bring greater precision, earlier intervention, and improved continuity of care across the patient journey.
The company’s featured diagnostics include:
- JOINTstat® (14-3-3eta): A blood test that aids in the diagnosis and monitoring of rheumatoid arthritis (RA).
- SPINEstat™ (Anti-14-3-3eta Multiplex): A first-in-class diagnostic blood test for the early and accurate diagnosis of axial spondyloarthritis (axSpA), helping clinicians distinguish inflammatory disease from mechanical back pain.
By sponsoring and attending Ten Topics 2025, Augurex is reaffirming its commitment to advancing precision diagnostics and collaborating with the rheumatology community to transform autoimmune care.
For more details about the event, visit:
Ten Topics in Rheumatology 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com